Krystal Current Deferred Revenue from 2010 to 2024
| KRYS Stock | USD 196.91 0.39 0.20% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter -2.1 M | Current Value -2 M | Quarterly Volatility 4.3 M |
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 23.8 M, Interest Income of 23.8 M or Depreciation And Amortization of 5.3 M, as well as many indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.11. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
Krystal | Current Deferred Revenue |
Latest Krystal Biotech's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Krystal Biotech over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Krystal Biotech's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Krystal Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,402,889 | |
| Coefficient Of Variation | 179.17 | |
| Mean Deviation | 2,198,296 | |
| Median | 2,104,000 | |
| Standard Deviation | 4,305,355 | |
| Sample Variance | 18.5T | |
| Range | 18.5M | |
| R-Value | (0.04) | |
| Mean Square Error | 19.9T | |
| R-Squared | 0 | |
| Significance | 0.90 | |
| Slope | (35,421) | |
| Total Sum of Squares | 259.5T |
Krystal Current Deferred Revenue History
About Krystal Biotech Financial Statements
Krystal Biotech shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -2.1 M | -2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.